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ER␣ and ER␤. Fluorescence resonance energy transfer and
protease digestion studies showed that MF101 produces a different conformation in ER␣ from ER␤ when compared with
the conformations produced by estradiol. The specific conformational change induced by MF101 allows ER␤ to bind to
an estrogen response element and recruit coregulatory proteins that are required for gene activation. MF101 did not
activate the ER␣-regulated proliferative genes, c-myc and cyclin D1, or stimulate MCF-7 breast cancer cell proliferation or
tumor formation in a mouse xenograft model. Our results demonstrate that herbal ER␤-selective estrogens may be a safer
alternative for hormone therapy than estrogens that nonselectively activate both ER subtypes. (Endocrinology 148:
538 –547, 2007)

Novel estrogenic therapies are needed that ameliorate menopausal symptoms and have the bone-sparing effects of endogenous estrogens but do not promote breast or uterine cancer.
Recent evidence suggests that selective activation of the estrogen receptor (ER)-␤ subtype inhibits breast cancer cell proliferation. To establish whether ER␤-selective ligands represent a viable approach to improve hormone therapy, we
investigated whether the estrogenic activities present in an
herbal extract, MF101, used to treat hot flashes, are ER␤ selective. MF101 promoted ER␤, but not ER␣, activation of an
estrogen response element upstream of the luciferase reporter gene. MF101 also selectively regulates transcription of
endogenous genes through ER␤. The ER␤ selectivity was not
due to differential binding because MF101 binds equally to

M

among postmenopausal women, and many of them reluctantly stopped taking estrogens despite the lack of effective
alternatives to treat hot flashes (10). The WHI findings created a large unmet need for effective alternatives to HT for
menopausal symptoms. Selective estrogen receptor modulators (SERMs) have been introduced as an alternative to
estrogens (7). The SERMs, raloxifene and tamoxifen, enhance
bone mineral density (11, 12), and raloxifene is an approved
drug for osteoporosis prevention (13). Unlike estrogens,
raloxifene and tamoxifen decrease the incidence of breast
cancer (14, 15). Despite these important effects, raloxifene
and tamoxifen increase the incidence of hot flashes (16).
Thus, the only effective estrogens for hot flashes are those
that cause cancer.
The discovery of safer estrogens for HT requires a greater
understanding of the role of estrogen receptor (ER) subtypes
in causing clinical effects. Estrogen signaling pathways are
mediated by two ERs, ER␣ and ER␤ (17, 18). Whereas the
exact physiological roles of the two ER subtypes remain
unknown, it is clear that ER␣ and ER␤ have different biological roles. The ER␣ and ER␤ knockout mice exhibit different phenotypes (19) and the genes regulated by estradiol
and SERMs with ER␣ are distinct from those regulated by
ER␤ (20). These studies suggest that drugs targeted selectively to only ER␣ or ER␤ will produce more selective clinical
effects, rather than the global effects elicited by estrogens
used in current HT regimens that regulate both ER subtypes.
Based on the observation that ER␣ promotes proliferation of

ENOPAUSE IS ASSOCIATED with the onset of hot
flashes, night sweats, mood changes, and urogenital
atrophy, which many women find distressing enough to seek
medical management for relief. Estrogens in the form of
hormone therapy (HT) have been the standard treatment for
menopausal symptoms for decades. Although HT is the most
effective treatment for hot flashes, the Women’s Health Initiative (WHI) trial found that the combination of estrogen
and progestin increases a woman’s risk for heart disease,
stroke, breast cancer, venous thromboembolic events, and
dementia (1–5) and does not improve quality of life indices
such as emotional and sexual functioning and vitality (6, 7).
In a second arm of the WHI study, estrogen only failed to
demonstrate any cardiovascular benefit in older women and
was found to increase the risk of stroke, venous thromboembolism, and dementia (8, 9).
The adverse effects of HT has caused considerable concern
First Published Online November 9, 2006
Abbreviations: CBP, cAMP response element-binding protein; CFP,
cyan fluorescent protein; ChIP, chromatin immunoprecipitation; DES,
diethylstilbestrol; E2, estradiol; ER, estrogen receptor; ERE, estrogen
response element; FRET, fluorescence resonance energy transfer; GRIP1,
glucocorticoid interacting protein 1; HT, hormone therapy; Luc, luciferase; SERM, selective estrogen receptor modulator; tk, thymidine kinase; WHI, Women’s Health Initiative; YFP, yellow fluorescent protein.
Endocrinology is published monthly by The Endocrine Society (http://
www.endo-society.org), the foremost professional society serving the
endocrine community.
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breast cancer cells, whereas ER␤ acts as tumor suppressor
and that both forms are effective in transcriptional repression
of inflammatory genes responsible for osteoporosis (21), we
hypothesize that ER␤-selective agonists might be a safer
alternative for long-term HT.
Our finding that soy contains phytoestrogens that selectively trigger ER␤ transcriptional pathways (22) suggests
that other botanical products might be a source of ER␤ agonists. We have been investigating the effects of a botanical
extract, MF101, on hot flashes in postmenopausal women.
Preliminary findings in a phase 1 trial with 22 postmenopausal women found that MF101 reduced hot flashes and did
not produce any adverse effects (data not shown). MF101 is
approved by the Food and Drug Administration (FDA) for
an ongoing phase 2, randomized, placebo-controlled trial for
the treatment of hot flashes (http://clinicaltrials.gov/show/
NCT00119665). MF101 is composed of 22 individual plant
species. The entire formula and its individual herbs were
selected based on the known pharmacology of the herbs and
traditional therapeutic uses in Chinese medicine for the treatment of vasomotor symptoms. An attempt was also made to
select herbs that do not promote cancer while simultaneously
treating symptoms. We used a molecular approach to determine whether MF101 in its native mode of administration
has selective ER activity as a scientific basis for the mechanism of action that can be potentially translated clinically to
prevent hot flashes. In this study, we demonstrate that
MF101 is a selective ER␤ agonist on gene regulation and does
not stimulate breast cancer cell proliferation or uterine
growth. These results suggest that ER␤-selective estrogens
might be safer than current estrogens in HT that activate both
ER␣ and ER␤.
Materials and Methods
MF101 preparation and extraction
MF101 is an ethanol/aqueous extract of the 22 herb species listed in
supplemental Table 1 (published as supplemental data on The Endocrine Society’s Journals Online web site at http://endo.endojournals.org)
that was manufactured by Kaiser Pharmaceuticals, Ltd. (Taichong, Taiwan) for Bionovo, Inc. (Emeryville, CA) under U.S. FDA investigational
new drug no. 58, 267. Herbs are harvested at the proper season and
geographical location to ensure proper botanical identification and reduce variability in yield for pharmaceutical application. The herbs are
identified by a botanist before processing. Based on traditional Chinese
medical application and pharmacology, each plant part used in the
extract is dried and cut for extraction. Half the amount (6 g) of the herb
Anemarrhenae asphoeloides is extracted in 60 ml of 95% EtOH (1:10) for 72 h
at room temperature. The extract and the plant material are than mixed
with the rest of the 22 herbs (261 g remaining) with 2670 ml of distilled
H2O (1:10) and heated at 70 –72 C for 60 min in a reverse steam vat. The
extract is concentrated by vacuum drying at below freezing temperature
to avoid crystallization. The concentrated extract is spray dried with
corn or rice starch and ground up dry plants to form a powder. The dry
soluble solids to nonsoluble solids ratio is 53.3% soluble solids to 46.7%
starch and cellulose from the plants. The powder is tested for heavy
metal, microbiological, and chemical contamination to comply with
FDA, cGMP drug manufacturing standards. The extract is again tested
with the chemical standards using HPLC to ensure their presence in the
final extract. Two chemical standards, nyasol and bakuchiol, as well as
the whole extract were quantified using an API-4000 MS/MS system
(Sciex/Applied Biosystems, Foster City, CA) in negative multiple reaction monitoring mode. For experiments, MF101 is extracted in water.
Details on the preparation (supplemental Appendix 1, published on
The Endocrine Society’s Journals Online web site at http://endo.
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endojournals.org) and composition (supplemental Tables 1 and 2) and
botanical names (supplemental Table 2) of MF101 are provided in supplemental material.

Cell culture
The MCF-7, U2OS, and HEK293 cell lines were cultured and maintained as previously described (20, 23). The U2OS cells expressing a
tetracycline-inducible ER␣ or ER␤ cDNA were prepared and maintained
as previously described (20).

Transfection assays
U2OS cells were collected, transferred to a cuvette, and then electroporated with a gene pulser (Bio-Rad Laboratories, Hercules, CA) as
previously described using 3 g ERE-tk-Luc and 1 g of ER␣ or ER␤
expression vectors (22). Transfection of the HEK293 with CFP-ER␣-YFP
or CFP-ER␤-YFP was done as previously described (24).

ER binding assays
The relative binding affinity of MF101 to full-length ER␣ and ER␤ was
determined using ER␣ and ER␤ competitor assay kits, according to the
manufacturer’s instructions (Invitrogen Life Technologies, Carlsbad,
CA). Fluorescence polarization of the fluorophore-tagged estrogen
bound to ER␣ and ER␤ in the presence of increasing amounts of competitor ligand or extract was determined (five readings per well; 0.1 sec
integration time; entire plate read eight times; G factor ⫽ 0.91) using the
Analyst AD plate-reader (LJL Biosystems, Sunnyvale, CA) with fluorescein excitation (485 nm) and emission (530 nm) filters. Each MF101
dose was performed in triplicate, and the relative error was determined
by calculating the se of three values from the mean.

Protease protection assay
35
S-labeled ER␣ and ER␤ were synthesized in vitro with the TnT T7
quick coupled transcription/translation system (Promega Corp., Madison, WI). One microliter of in vitro translation product was diluted to
16 l with 50 mm Tris-Cl (pH 7.6) containing estradiol (E2), MF101, or
0.01% ethanol control. The samples were incubated on ice for 30 min.
Varying concentrations of elastase (0, 0.065, 0.125, 0.25, 0.5, or 1 g) were
added to each sample and incubated for 5 min at room temperature. The
assay was terminated with 20 l SDS-PAGE sample buffer. The samples
were heated for 10 min at 98 C and resolved with a 10% polyacrylamide
gel. Gels were fixed and dried, and radiolabeled proteolytic fragments
were detected by autoradiography.

Chromatin immunoprecipitation (ChIP)
After a 45-min treatment with MF101, U2OS-ER␣ and U2OS-ER␤ cells
were fixed in 1% formaldehyde solution and ChIP was done as previously described (21). Immunoprecipitations were performed overnight
at 4 C with anti-ER␣ (1D5; Dako, Carpinteria, CA), anti-ER␤ (6A12, 14C8,
and 7B10, GeneTex, San Antonio, TX), anti-cAMP response elementbinding protein (CBP) (A-22, Santa Cruz Biotechnology, Santa Cruz,
CA), anti-glucocorticoid interacting protein 1 (GRIP1) (ab9261, Abcam,
Cambridge, MA), and anti-RNA polymerase II (Santa Cruz Biotechnology) antibodies. PCR was done with keratin 19 primers, 5⬘-TCCAGCCTGGGTGACAGAGC and 5⬘-TCCAAGTTCACCCCAACCTGA, which
span the consensus estrogen response element (ERE) and half-ERE in the
keratin 19 enhancer region (25).

Cell proliferation assays
MCF-7 breast cancer cells were cultured in phenol-free DMEM/F-12
media containing 4% stripped fetal bovine serum for 1 wk before treatment. Five thousand cells were plated in 24-well plates and treated with
vehicle, E2, or MF101 for 7 d. 3H-thymidine incorporation was used to
quantify DNA synthesis.

Xenograft studies in nude mice
MCF-7 (250,000) cells were aggregated in suspension and then resuspended in 25 l neutralized collagen (26). The cells were then grafted
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under the kidney capsule of intact nude mouse as described and illustrated in detail on the Web site (http://mammary.nih.gov/tools/mousework/Cunha001/index.html). Animals were untreated (control),
treated with a sc diethylstilbestrol (DES) pellet (2 mg) or 0.5 ml (25
mg/dose) MF101 every other day by oral gavage. Tumors were analyzed
1 month after grafting. The animal studies were carried out with approval from the University of California, San Francisco, Committee on
Animal Research.

Real-time RT-PCR
Total RNA was isolated using Trizol (Invitrogen Life Technologies)
and reverse transcription reactions were performed using iScript cDNA
synthesis kit (Bio-Rad). Real-time quantitative PCR was performed using SYBR Green Supermix with an iCycler thermal cycler (Bio-Rad). We
used the following primers: c-myc forward 5⬘-GCCCCTCAACGTTAGCTTCA-3⬘, reverse 5⬘-TTCCAGATATCCTCGCTGGG-3⬘; cyclin D1
forward 5⬘-AACTACCTGGACCGCTTCCT-3⬘, reverse 5⬘-CCACTTGAGCTTGTTCACCA-3⬘; Gus forward 5⬘-CTCATTTGGAATTTTGCCGATT-3⬘, reverse 5⬘-CCGAGTGAAGATCCCCTTTTTA-3⬘; keratin 19
forward 5⬘-CCAGGTCAGTGTGGAGGTGG-3⬘, reverse 5⬘-TTGGCTTCGCATGTCACTCA-3⬘; TNF␣ forward 5⬘-GAGTGACAAGCCTGTAGCCCATGTTG-3⬘, reverse 5⬘-GCAATGATCCCAAAGTAGACCTGCCC-3⬘; IL-6 forward 5⬘-TACCCCCAGGAGAAGATTCC-3⬘, reverse
5⬘-TTTTCTGCCAGTGCCTCTTT-3⬘; and ␤-actin forward 5⬘-AGCCTCGCCTTTGCCGA-3⬘, reverse 5⬘-CTGGTGCCTGGGGCG-3⬘.
The data were collected and analyzed using the comparative cycle
threshold method using Gus or ␤-actin expression as the reference gene.

Fluorescence resonance energy transfer (FRET) analysis
A day before transfection, HEK293 cells (n ⫽ 200,000) were plated into
each well of a six-well dish and grown in DMEM-H21 supplemented
with 5% charcoal-stripped fetal calf serum. CFP-ER␣-YFP (24) or CFPER␤-YFP (500 ng/well) was transfected into cells using Lipofectamine
Plus (Invitrogen). The day after transfection, 100,000 cells/well were
replated in black, clear-bottomed, 96-well plates (Costar, Cambridge,
MA) in the presence or absence of 10 nm E2 or MF101. Cells were fixed
in 4% paraformaldehyde in PBS before reading on the fluorescence plate
reader. For FRET detection on the fluorescence plate reader (Safire;
Tecan, Durham, NC), measurements were taken from the bottom of the
plate with the following settings: yellow fluorescent protein (YFP), excitation at 485 nm/emission at 527 nm; cyan fluorescent protein (CFP),
excitation at 435 nm/emission at 485 nm; and FRET, excitation at 435
nm/emission at 527 nm. Each plate contained an untransfected cell
control (background), and each data point was collected in quadruplicate. FRET to donor ratios were calculated after background subtraction
and correction for acceptor (YFP) contribution into the FRET spectrum
(24).

Results
The herbal extract, MF101, selectively activates
transcription with ER␤

The individual herbs and the formulation of MF101 are
shown in supplemental Table 1. We initially examined the
relative contributions of ER␣ and ER␤ to MF101 activity in
standard luciferase (Luc) reporter assays. U2OS osteosarcoma cells were cotransfected with a classical ERE upstream
of a minimal thymidine kinase (tk) promoter (ERE-tk-Luc)
and expression vectors for human ER␣ or ER␤. MF101 produced a dose-dependent activation of ERE-tk-Luc with ER␤
but not with ER␣ (Fig. 1A). One hundred twenty-five micrograms of MF101 caused the activation equivalent to 10 nm
E2 (Fig. 1B). The ER antagonists, ICI 182,780, raloxifene, and
tamoxifen, blocked the activation by MF101 (Fig. 1B), indicating that the effect of MF101 is mediated through ER␤.
MF101 also did not activate ERE-tk-Luc with ER␣ in other
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cell types, including HeLa, MDA-MB-453, and Ishikawa cells
(Fig. 1C). Similar to U2OS cells, MF101 activated ERE-tk-Luc
with ER␤ to the same magnitude as E2 in these three cell lines
(Fig. 1D). The ER-subtype selectivity was examined in U2OS
cells stably transfected with a tetracycline-inducible ER␣ or
ER␤ (20) using the keratin 19 gene, which contains an ERE
(25). E2 activated the keratin 19 gene in both U2OS-ER␤ (Fig.
1E) and U2OS-ER␣ cells (Fig. 1F), whereas MF101 produced
a dose-dependent increase in keratin 19 mRNA only in the
U2OS-ER␤ cells.
Estrogens possess antiinflammatory properties by repressing the expression of inflammatory genes (21). The repression of the TNF␣ or IL-6 genes might be an important mechanism by which estrogens prevent inflammatory conditions,
such as osteoporosis (27). To investigate whether MF101
represses the expression of the TNF␣ and IL-6 genes, the
tetracycline-inducible ER␣ or ER␤ cells were treated with E2
or MF101. Because the basal expression of these genes is very
low, it is necessary to activate these genes with TNF␣ to
observe repression. TNF␣ produced a large increase in TNF␣
and IL-6 mRNA (Fig. 2, A–D), which was inhibited by E2 in
both the U2OS-ER␣ (Fig. 2, A and B) and U2OS-ER␤ (Fig. 2,
C and D) cells. MF101 repressed the TNF␣ activation of the
TNF␣ and IL-6 genes in the U2OS-ER␤ cells (Fig. 2, C and D)
but not in the U2OS-ER␣ (Fig. 2, A and B) cells. These studies
demonstrate that MF101 selectively triggers ER␤-mediated
transcriptional pathways.
MF101 binds equally to ER␣ and ER␤ and induces
conformational changes distinct from E2

Phytoestrogens found in soybeans, such as genistein, bind
to ER␤ with a 7- to 30-fold higher affinity, compared with
ER␣ (28, 29). These data suggest that MF101 may act as an
ER␤-selective agonist by virtue of a higher binding affinity
to ER␤. However, competition binding curves show that
MF101 binds equally to ER␣ and ER␤ (Fig. 3A). The findings
that MF101 binds to ER␣ but does not stimulate it to activate
genes suggest that MF101 induces a functional conformation
only with ER␤. Schaufele et al. (24) demonstrated that FRET
could be used to discriminate conformational changes in the
androgen receptor and ER␣ that correlate with ligand binding. The FRET signal is derived from intramolecular conformational changes that alter the orientation of the N and C
termini of the fluorescent tags, bringing the donor (CFP) and
the acceptor (YFP) in close proximity.
Conformational changes induced by MF101 in ER␣ and
ER␤ were examined by FRET in HEK293 cells transfected
with vectors containing the cDNA for ER␣ or ER␤ fused
between CFP and YFP to create the chimeric proteins, CFPER␣-YFP and CFP-ER␤-YFP. HEK293 cells were used because high-transfection efficiency is required for FRET analysis. After cells were transfected, they were treated with E2
or MF101 and FRET:donor was measured (see Materials and
Methods). A slightly higher basal FRET:donor was observed
with CFP-ER␤-YFP, compared with CFP-ER␣-YFP (Fig. 3, B
and C), which is probably due to differences in basal conformation. An increase in FRET:donor was observed with
both ER␣ and ER␤ at similar doses of E2 (Fig. 3B) and MF101
(Fig. 3C). These results provide additional evidence that

The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 27 March 2015. at 09:24 For personal use only. No other uses without permission. . All rights reserved.

Cvoro et al. • The Herbal Extract, MF101, Is an ER␤-Selective Agonist

Endocrinology, February 2007, 148(2):538 –547

541

FIG. 1. MF101 selectively activates transcription through ER␤. A, A single copy of the vitellogenin A2 ERE upstream of the minimal tk promoter
(ERE tk-Luc) was cotransfected into U2OS cells with expression vectors for human ER␣ or ER␤. After transfection, the cells were treated for
18 h with increasing amounts of MF101 and luciferase activity was measured. RLU, Relative light units. B, MF101 activation of ERE tk-Luc
is blocked by antiestrogens. U2OS cells were cotransfected with ERE tk-Luc and an expression vector for ER␤. The cells were treated with 10
nM E2 or 125 g/ml MF101 in the absence or presence of 1 M ICI, raloxifene (Ral), or tamoxifen (Tam) for 18 h. Cont, Control. C and D, MF101
is an ER␤-selective agonist in human cervical (HeLa), breast (MDA-MB-453), and endometrial (Ishikawa) cell lines. Cells were cotransfected
with ERE tk-Luc and an expression vector for human ER␣ (C) or ER␤ (D). The cells were treated with 10 nM E2 or 125 g/ml MF101 for 18 h,
and luciferase activity was measured. E and F, MF101 selectively activates transcription of the endogenous keratin 19 gene through ER␤. U2OS
cells stably transfected with ER␤ (E) or ER␣ (F) were treated with 10 nM E2 or increasing amounts of MF101 for 18 h. The level of keratin 19
mRNA was measured by real-time PCR. Each data point is the average of triplicate determinations ⫾ SEM.

MF101 binds equally to ER␣ and ER␤. Because ER␣ and ER␤
have different primary structures, we compared the conformational responses produced by MF101 vs. E2. Compared
with the 10 nm E2 response, MF101 increased FRET:donor by
42% with ER␣, whereas the same dose of MF101 increased
FRET:donor by 15% with ER␤ (Fig. 3D). The FRET studies

indicate that MF101 brings the N and C termini of ER␣ into
a much closer proximity than that induced by E2, which leads
to the higher FRET:donor observed with ER␣. These results
demonstrate that MF101 produces a conformational change
in ER␤ that closely resembles the active conformation elicited
by E2 in ER␤, whereas MF101 produces a markedly different
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FIG. 2. MF101 selectively represses transcription of the TNF␣ and IL-6 genes through ER␤. U2OS-ER␣ (A and B) and U2OS-ER␤ (C and D)
cells were treated with 1 g/ml doxycycline for 18 h to induce ER expression. Cells were then treated with 5 ng/ml TNF␣ for 2 h and 100 nM
E2 or 125 g/ml MF101 for the indicated times. TNF␣ (A and C) and IL-6 (B and D) mRNA levels were determined by real-time PCR. Each
data point is the average of triplicate determinations ⫾ SEM.

conformation in ER␣, compared with the one produced by
E2.
To further investigate whether MF101 changes the conformation of ER␣ and ER␤ without the fluorescent tags, we
performed limited proteolysis to probe the conformational
features of ER␣ and ER␤ when bound with MF101 or E2.
Radiolabeled ER␣ and ER␤ were synthesized in an in vitro
transcription and translation system and digested with elastase for increasing times. MF101 and E2 produced a distinct
digestion pattern of ER␤ (Fig. 4A) and ER␣ (Fig. 4B), compared with the control. The digestion pattern of ER␤ was
different with E2 and MF101 (Fig. 4A). The strongest protection is observed when ER␤ is bound with E2 as demonstrated by the presence of several protected fragments (three
arrows) at the highest elastase concentrations, which are less
prominent in the control and MF101 samples sample. When
bound with MF101, ER␣ demonstrates a slight increase in
protection to elastase, compared with the control, but less
than that observed with E2 (Fig. 4B). MF101 also produced a
distinct pattern, compared with the control or E2. The two
arrows show several protected fragments of ER␣ with E2,
compared with the MF101-treated ER␣ (Fig. 4B). The FRET
and protease digestion studies demonstrate that MF101
binds to ER␣ and ER␤ and induces conformational changes
in both ER subtypes.

MF101 causes the selective recruitment of ER␤ and
coregulatory proteins to target genes

Our studies suggests that upon MF101 binding, ER␤
adopts a different overall conformation from ER␣, which
could prevent ER␣ from binding to the regulatory elements
or recruiting coregulatory proteins that are required for gene
activation (30 –32). To investigate these possibilities, we performed ChIP on the keratin 19 gene because E2 recruits ER to
the keratin 19 ERE in both U2OS-ER␣ and U2OS-ER␤ cells as
well as RNA polymerase II and coregulatory proteins (20,
21). ChIP shows that MF101 recruited ER␤ but not ER␣ to the
keratin 19 gene (Fig. 4C). MF101 also induced recruitment of
RNA polymerase II, GRIP1 and CBP to the keratin 19 gene
selectively in U2OS-ER␤ cells. These results demonstrate that
MF101 produces a conformation in ER␤ but not in ER␣ that
allows the MF101-ER␤ complex to bind an ERE and recruit
coregulatory proteins that activate the keratin 19 gene.
MF101 does not stimulate MCF-7 cell tumor formation or
uterine growth in mouse xenograft models

A critical feature of an alternative estrogen for menopausal
symptoms is that it does not increase the risk for breast and
uterine cancer. We investigated whether MF101 has growthpromoting properties in MCF-7 breast cancer cells, which
express only ER␣. Unlike E2, MF101 did not stimulate cell
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FIG. 3. ER␤-selectivity of MF101 results from the formation of a functional conformation that allows ER␤ binding to an ERE. A, Purified ER␣
or ER␤ were incubated with fluorescent E2 in the absence or presence of increasing amounts of MF101. B and C, HEK293 cells were transfected
with CFP-ER␤-YFP or CFP-ER␣-YFP and then treated with increasing amounts of E2 (B) or MF101 (C). After 24 h FRET:donor was measured.
D, FRET:donor with MF101 (150 g/ml) expressed relative to the FRET:donor produced by 10 E2 nM. The results shown in D are an average
of four experiments and are not derived directly from the data in B and C.

proliferation of MCF-7 cells (Fig. 5A). MF101 also did not
activate c-myc (Fig. 5B) or cyclin D1 (Fig. 5C) genes, which are
key genes involved in breast cancer induced by E2 (33, 34).
To determine whether MF101 causes tumor formation,
MCF-7 cells were grafted under the kidney capsule of nude
mice. In control mice, only small tumors were formed after
1 month (Fig. 5D). In contrast, large tumors developed in
mice treated with DES (Fig. 5E). At a dose comparable with
the amount used to treat hot flashes in women, MF101 did
not increase the size of the tumor graft (Fig. 5, F and G) or
uterine weight (Fig. 5H), compared with control mice. These
data demonstrate that MF101 does not promote proliferation
of MCF-7 cells or uterine growth and are consistent with the
hypothesis that ER␣ mediates the proliferative effects of E2
(22, 23, 35).

Discussion

Hot flashes are experienced by most menopausal women.
Estrogens are the most effective and widely used therapy for
hot flashes in the United States. However, the findings of the
WHI (3, 8) have caused many women to stop taking HT (10)
and to explore alternative therapies in search of a safer treatment for vasomotor symptoms (36). Herbal formulas, which
have been used in China for centuries, might provide a
platform of potential drugs to treat hot flashes. Whereas it is
known that some herbs have estrogenic activity (37, 38), it is
unclear whether they are effective for treating hot flashes and
other clinical symptoms. Clearly, the adverse of effects of HT
make it worthwhile to begin to explore the potential benefits
of herbs for menopausal symptoms. However, it is possible
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FIG. 4. MF101 changes conformation in ER␣ and ER␤ and selectively recruits ER␤ and coregulators to the keratin 19 gene. 35S-methioninelabeled ER␤ (A) or ER␣ (B) was synthesized in an in vitro transcription/translation system and then incubated with increasing amount of elastase
in the presence of vehicle (control), E2, or MF101. The protein fragments were separated by SDS-PAGE and the dried gels were exposed to x-ray
film. C, U2OS-ER␤ or U2OS-ER␣ cells were treated with MF101 for 45 min, and then ChIP was performed using antibodies to RNA polymerase
(pol) II, GRIP1, CBP, or ERs. The PCR product spans the ERE of the keratin 19 gene.

that such estrogenic herbs may elicit the same adverse effects
associated with estrogens currently used in HT, unless those
herbs possess some form of selective ER action. Here we
examined whether the herbal formula, MF101, primarily designed to treat hot flashes, has selective estrogen receptor
activity.
We demonstrated that MF101 triggers only ER␤-mediated
transcriptional pathways because it activated ERE-tk-Luc
and the endogenous keratin 19 gene in U2OS-ER␤ cells but
not in U2OS-ER␣ cells. MF101 also repressed TNF␣ and IL-6
genes only in U2OS-ER␤ cells. Whereas the magnitude of
regulation was equivalent to E2, the dose of MF101 needed
for ER␤ activation or repression is about 50,000-fold greater
than that of E2 on a weight basis. However, because MF101
is a crude extract, the dose of the estrogenic components in
the mixture in comparison with E2 is not known. Surprisingly, MF101 binds equally to purified ER␣ and ER␤. The
binding of MF101 to ER␣ was also demonstrated with FRET
and protease digestion studies by showing that MF101
changed the conformation of ER␣. However, we found that
MF101 did not antagonize the activation of ERE-tk-Luc or the
keratin 19 gene, even though it binds equally to ER␣ and ER␤.
The lack of antagonist activity is due to the much weaker
binding of MF101 to ER␣, compared with E2 (data not
shown). The pure compounds isolated from MF101 will allow us to evaluate the ER␣ antagonist activity in MF101. The
FRET studies also demonstrated when MF101 is bound to

ER␤, the overall conformation more closely resembles the
active conformation of ER␤ produced by E2, compared with
the conformational change of ER␣ when MF101 vs. E2 is
bound. The ChIP studies showed that, even though MF101
produces a conformational change in both ER␣ and ER␤,
only the conformation induced in ER␤ is capable of binding
to an ERE and recruiting coregulator proteins. These results
demonstrate that the ER␤-selectivity of MF101 results from
its capacity to create a distinct conformation that allows ER␤
to bind to an ERE and recruit coregulators, such as GRIP1 and
CBP. The selective recruitment of coactivators to ER␤ by
MF101 is clinically important because ER␣ mediates proliferation and tumor formation of MCF-7 breast cancer cells,
whereas ER␤ acts as a tumor suppressor in ER-positive breast
cancer cells (13, 29). The inability of MF101 to promote the
interaction of ER␣ with regulatory elements and recruit coactivators can account for the observation that MF101 did not
activate c-myc and cyclin D1 genes in MCF-7 cells or stimulate
tumor formation and uterine size in a mouse xenograft
model.
Whereas the activation function of ER␣ is associated with
the proliferative effects of estrogens, the repression of inflammatory genes (21) is likely an important mechanism by
which estrogens prevent osteoporosis (39) and possibly coronary heart disease in younger women (40). Estrogens repress inflammatory genes through both ER␣ and ER␤, but
the repression is about 20 times more effective with ER␤ (41).
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FIG. 5. MF101 does not stimulate proliferation or tumor formation of MCF-7 breast cancer cells. A, MCF-7 cells in stripped serum were treated
with E2 or MF101 for 7 d, and the amount of 3H-thymidine incorporation was measured to determine DNA synthesis. B and C, MF101 does
not activate c-myc or cyclin D1 gene transcription. MCF-7 cells were treated with 10 nM E2 or increasing amounts of MF101. After 1 or 3 h,
total RNA was isolated and the level of c-myc (B) or cyclin D1 (C) mRNA, respectively, was determined by real-time PCR. D–H, MCF-7 cells
were grafted under the kidney capsule of intact female nude mice. Mice were untreated (control) or treated with a sc DES pellet (2 mg) or 0.5
ml MF101 every other day by oral gavage. After 1 month, the tumors and uterus were removed and analyzed for size and weight. Gross
morphology of the xenografts in control (D), DES (E), and MF101 (F) treated mice is shown. The arrow points to the site of grafting. Average
weights ⫾ SEM of tumor grafts (G) and uterus (H) are from five mice in each group.

Our results demonstrate that ER␤-selective drugs, such as
MF101, do not activate the ER␣-mediated proliferative pathways but trigger the antiinflammatory pathway by activating
ER␤. The repression of inflammatory genes by ER␤, such as
TNF␣ and IL-6, is consistent with the observations that a
synthetic ER␤-selective agonist is effective at treating several
inflammatory conditions in animal models (42) and that ER␤
is important for the protective effect of estrogens on the
vascular system (43). Our findings suggest that drugs targeted to ER␤ will preserve the antiinflammatory action but
will be devoid of the proliferative effects of estrogens used
in HT.
Whereas the role of ER␤ in hot flashes is unknown our
findings provide proof of principle that ER␤-selective drugs
should not have the same toxicity profile as the currently
available estrogens, which have been shown to increase the
risk of both breast and uterine cancer. Moreover, our results
are consistent with previously reported data showing that a
synthetic ER␤-selective ligand (ERB-041) did not elicit a proliferative response in the mammary gland or uterus of rats
(42). Whereas these preclinical studies indicate that it is unlikely ER␤-selective drugs will promote breast or uterine
cancer, it is critical to translate our basic research findings by
determining whether ER␤-selective agonists are safe and
effective at relieving hot flashes in women. Phase 1 studies
indicated that MF101 was well tolerated and provided a
preliminary indication that hot flashes were reduced (data
not shown). However, these uncontrolled studies await confirmation in a larger clinical trial. To begin this process, we
launched a multicenter, randomized, double-blind, placebo-

controlled phase 2 trial in a group of 180 postmenopausal
women to evaluate the efficacy of two different doses of
MF101 to reduce hot flashes (http://clinicaltrials.gov/show/
NCT00119665). Whereas our findings suggest that any potential benefits of MF101 on hot flashes would be mediated
through ER␤, it is possible MF101 might work through ER␣
in the brain rather than ER␤ because we have not examined
the selectivity of MF101 in neurons.
We demonstrated that despite containing many different
herbs, the MF101 extract is ER␤ selective. Examining the
effects of the crude MF101 on estrogenic activity has several
advantages. First, it is important to study MF101 because it
is currently being studied in clinical trials as a drug under an
FDA investigational new drug. Second, MF101 might be
more effective at preventing hot flashes and be a better drug
than the individual compounds because of synergy among
many compounds. Third, MF101 provides a starting point to
isolate pure ER␤-selective estrogens. Our studies have found
that MF101 contains at least six different ER␤-selective compounds by thin-layer chromatography, HPLC, and liquid
chromatography/mass spectrometry (data not shown). Our
results suggest that MF101 or pure ER␤-selective agonists
from MF101 might be a safer approach to manage menopausal symptoms because, unlike estrogens used currently in
HT, they do not cause the ER␣-mediated breast cancer cell
proliferation or uterine growth. Our study also provides a
scientific foundation to explore whether MF101 and other
ER␤-selective agonists from herbs prevent menopausal
symptoms, breast cancer, and inflammatory diseases asso-
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ciated with menopause, such as osteoporosis and cardiovascular disease.
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